Skip to content
Unknown statusPhase 2

A Single Ketamine Infusion Combined With Music for Suicidal Ideation

NCT04658420 · The University of Texas Health Science Center at Tyler

Closed to entry
Status
Not accepting participants
Phase 2
Phase
200
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

Suicidal ideation (SI) associated with major and bipolar depression is commonly seen in a wide range of clinical practice situations including the emergency room (ER). Current treatment regimens are often unsatisfactory. About a third of patients fail to respond to currently available therapy, and there are no currently FDA indicated rapid acting treatments for SI. Suboptimal outcomes have triggered the search for new, well-tolerated and more effective forms of treatment. Small clinical trials suggest that low dose (0.5mg/kg) ketamine is safe and effective for SI. We believe adding music during ketamine infusion may reduce anxiety and lead to more reduced SI based on available evidence. We are testing the hypothesis that a single infusion of ketamine combined with music enhances tolerability and improves outcomes in the treatment of SI when combined with treatment as usual in a factorial study design. One treatment with Ketamine + music will be compared to compared to one-time treatment with ketamine alone, music alone, or treatment as usual. 50 individuals with a depressive episode and suicidal ideation will receive intravenous (IV) ketamine 0.5mg/kg infused over 40 minutes once with 60 minutes of music, 50 individuals will receive IV ketamine without music, 50 subjects will receive 60 minutes of music once, and 50 patients will receive treatment as usual without ketamine or music. We anticipate that the ketamine + music group will have statistically significant indices of improvement in the primary outcome, suicidal ideation scores on the Scale for Suicidal Ideation (SSI) 4 weeks after the ketamine infusion. Secondary outcomes will include depression scores on the MontgomeryÅsberg Depression Rating Scale (MADRS) scale, adverse effects, and SSI scores at the end of 4 weeks. If, as we anticipate, the results indicate success of ketamine + music for SI, the work will identify new opportunities to more effectively manage patients with depression and suicidal ideation presenting to the ER.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Scale for Suicide Ideation (SSI)

    Measured over 4 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 64 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Adults age 18-64 * DSM-IV diagnosis of depressive episode as determined by the Mini International neuropsychiatric Interview criteria, and Montgomery Asberg Depression Rating Scale ≥ 28 * Suicidal ideation at baseline as and positive suicidal ideation defined as Scale for Suicidal Ideation score ≥4. * Diagnosis of Major depressive disorder, bipolar disorder, or substance induced mood disorder will be included. Exclusion Criteria: * Active psychotic symptoms * Current manic episode * Previous diagnosis of Schizophrenia or Schizoaffective disorder * Previous diagnosis of Intellectual disability or Autism Spectrum Disorder * Previous diagnosis of Major Neurocognitive Disorder * History of ketamine abuse or dependence * Hypersensitivity to esketamine, ketamine, or any of the excipients. Uncontrolled clinically significant medical conditions such as: * Respiratory illness requiring the use of oxygen * Previously documented prolonged QTc interval * Current Aneurysmal vascular disease * Arteriovenous malformation * Intracerebral hemorrhage * Unstable cardiac disease including history of myocardial infarction * Positive urine pregnancy test * Previous treatment of depression with Ketamine or Esketamine

Where

1 study site

FacilityCityRegionCountry
UT Health East TexasTylerTexasUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT04658420 on ClinicalTrials.gov →

Last updated in the registry 2021-05-07. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits